Cargando…
Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice
Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, and there is no standard and efficient therapy for it. Chitosan oligosaccharide (COS) is widely known to have various biological effects, and in this study we aimed to evaluate the liver-protective effect in diet-induced obese mice for a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669476/ https://www.ncbi.nlm.nih.gov/pubmed/31269758 http://dx.doi.org/10.3390/md17070391 |
_version_ | 1783440379238940672 |
---|---|
author | Qian, Minyi Lyu, Qianqian Liu, Yujie Hu, Haiyang Wang, Shilei Pan, Chuyue Duan, Xubin Gao, Yingsheng Qi, Lian-wen Liu, Weizhi Wang, Lirui |
author_facet | Qian, Minyi Lyu, Qianqian Liu, Yujie Hu, Haiyang Wang, Shilei Pan, Chuyue Duan, Xubin Gao, Yingsheng Qi, Lian-wen Liu, Weizhi Wang, Lirui |
author_sort | Qian, Minyi |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, and there is no standard and efficient therapy for it. Chitosan oligosaccharide (COS) is widely known to have various biological effects, and in this study we aimed to evaluate the liver-protective effect in diet-induced obese mice for an enzymatically digested product of COS called COS23 which is mainly composed of dimers and trimers. An integrated analysis of the lipidome and gut microbiome were performed to assess the effects of COS23 on lipids in plasma and the liver as well as on intestinal microbiota. Our results revealed that COS23 obviously attenuated hepatic steatosis and ameliorated liver injury in diet-induced obese mice. The hepatic toxic lipids—especially triglycerides (TGs) and free fatty acids (FFAs)—were decreased dramatically after COS23 treatment. COS23 regulated lipid-related pathways, especially inhibiting the expressions of FFA-synthesis-related genes and inflammation-related genes. Furthermore, COS23 could alter lipid profiles in plasma. More importantly, COS23 also decreased the abundance of Mucispirillum and increased the abundance of Coprococcus in gut microbiota and protected the intestinal barrier by up-regulating the expression of tight-junction-related genes. In conclusion, COS23, an enzymatically digested product of COS, might serve as a promising candidate in the clinical treatment of NAFLD. |
format | Online Article Text |
id | pubmed-6669476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66694762019-08-08 Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice Qian, Minyi Lyu, Qianqian Liu, Yujie Hu, Haiyang Wang, Shilei Pan, Chuyue Duan, Xubin Gao, Yingsheng Qi, Lian-wen Liu, Weizhi Wang, Lirui Mar Drugs Article Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, and there is no standard and efficient therapy for it. Chitosan oligosaccharide (COS) is widely known to have various biological effects, and in this study we aimed to evaluate the liver-protective effect in diet-induced obese mice for an enzymatically digested product of COS called COS23 which is mainly composed of dimers and trimers. An integrated analysis of the lipidome and gut microbiome were performed to assess the effects of COS23 on lipids in plasma and the liver as well as on intestinal microbiota. Our results revealed that COS23 obviously attenuated hepatic steatosis and ameliorated liver injury in diet-induced obese mice. The hepatic toxic lipids—especially triglycerides (TGs) and free fatty acids (FFAs)—were decreased dramatically after COS23 treatment. COS23 regulated lipid-related pathways, especially inhibiting the expressions of FFA-synthesis-related genes and inflammation-related genes. Furthermore, COS23 could alter lipid profiles in plasma. More importantly, COS23 also decreased the abundance of Mucispirillum and increased the abundance of Coprococcus in gut microbiota and protected the intestinal barrier by up-regulating the expression of tight-junction-related genes. In conclusion, COS23, an enzymatically digested product of COS, might serve as a promising candidate in the clinical treatment of NAFLD. MDPI 2019-07-02 /pmc/articles/PMC6669476/ /pubmed/31269758 http://dx.doi.org/10.3390/md17070391 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Qian, Minyi Lyu, Qianqian Liu, Yujie Hu, Haiyang Wang, Shilei Pan, Chuyue Duan, Xubin Gao, Yingsheng Qi, Lian-wen Liu, Weizhi Wang, Lirui Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice |
title | Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice |
title_full | Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice |
title_fullStr | Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice |
title_full_unstemmed | Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice |
title_short | Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice |
title_sort | chitosan oligosaccharide ameliorates nonalcoholic fatty liver disease (nafld) in diet-induced obese mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669476/ https://www.ncbi.nlm.nih.gov/pubmed/31269758 http://dx.doi.org/10.3390/md17070391 |
work_keys_str_mv | AT qianminyi chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT lyuqianqian chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT liuyujie chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT huhaiyang chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT wangshilei chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT panchuyue chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT duanxubin chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT gaoyingsheng chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT qilianwen chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT liuweizhi chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice AT wanglirui chitosanoligosaccharideamelioratesnonalcoholicfattyliverdiseasenafldindietinducedobesemice |